Please assess the completion status of the following clinical trial:

Trial Title: Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible to enter the study, each patient must comply with the following inclusion criteria:~* Provide written informed consent and aged between 18 and 75 years of age.~* Meets DSM-IV™ criteria for a primary diagnosis of schizophrenia.~* Not pregnant, if of reproductive potential agrees to remain abstinent or use adequate and reliable contraception for duration of study.~* Able and agrees to remain off prior antipsychotic medication for the duration of study.~* Good physical health on the basis of medical history, physical examination, and laboratory screening.~* Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits.~Exclusion Criteria:~* Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.~* Any chronic organic disease of the CNS (other than schizophrenia)~* Used investigational compound within 30 days.~* Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lurasidone 40mg (Type: EXPERIMENTAL): None
- Lurasidone 80mg (Type: EXPERIMENTAL): None
- Lurasidone 120mg (Type: EXPERIMENTAL): None
- Sugar Pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).